Nobody could be more qualified than Jack Hirsh [
[1]
] to comment five decades of progress in the field of antithrombotic therapy, as he
did in an authoritative review in the December issue of this Journal, along with his
coworkers and colleagues John Eikelboom and Noel Chan [
https://en.wikipedia.org/wiki/Jack_Hirsh, (last edited on 28 January 2020, at 20:16 (UTC)).
[2]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
https://en.wikipedia.org/wiki/Jack_Hirsh, (last edited on 28 January 2020, at 20:16 (UTC)).
- Fifty years of research on antithrombotic therapy: achievements and disappointments.EJIM. 2019; 70: 1-7
- Dosage and control of oral anticoagulants: an international collaborative survey.Br J Haematol. 1982; 51: 479-485
- An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis. results of the European multicenter advent trial.Thromb Haemost. 1997; 78: 997-1002
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.Lancet. 2014; 383: 955-962
- Direct-acting oral anticoagulants. The brain gets a break.JAMA Neurol. 2013; 70: 1483-1484
- Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism.Ann Intern Med. 2006; 144: 157-164
- Waste in the US health care system. Estimated costs and potential for savings.JAMA. 2019; 322: 1501-1509
- The genetic basis of antiplatelet and anticoagulant therapy: a pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Expert Opin Drug Metab Toxicol. 2017; 13: 725-739
- Antithrombotic therapy for VTE disease. Chest guideline and expert panel review.Chest. 2016; 149: 315-352
2018, (http://magicproject.org/).
- MAGIC research and innovation programme. Including practical issues and patient perspectives in rapid recommendations.BMJ. 2018; 363: k4871
Article info
Publication history
Published online: February 25, 2020
Accepted:
February 18,
2020
Received:
January 31,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
